Merck has known for a decade that its mumps vaccine is “far less effective” than it tells the government, and it falsified test results and sold millions of doses of “questionable efficacy,” flooding and monopolizing the market, a primary caregiver claims in a federal antitrust class action.
Alabama-based Chatom Primary Care sued Merck on Monday, the week after the unsealing of a False Claims Act complaint two relators filed in 2010.
Those relators, Stephen Krahling and Joan Wlochowski, were Merck virologists who claim in their unsealed complaint that they “witnessed firsthand the improper testing and data falsification in which Merck engaged to artificially inflate the vaccine’s efficacy findings.”
… seeks to represent the class of all those who bought Merck’s mumps vaccine from Jan. 1, 1999 to today. It seeks damages for monopolization under the Sherman Act, violation of state consumer protection laws, unjust enrichment and breach of warranty.
Tiny URL for this post: http://tinyurl.com/7okp62a